Skip to main content
Top
Published in: Osteoporosis International 2/2003

01-02-2003 | Original Article

Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenopausal women after 5 years

Authors: E. D. Newman, W. T. Ayoub, R. H. Starkey, J. M. Diehl, G. C. Wood

Published in: Osteoporosis International | Issue 2/2003

Login to get access

Abstract

A 5 year observational study is reported which reviews the implementation of the Geisinger Health System Osteoporosis Disease Management Program. This program includes Osteoporosis Clinical Practice Guidelines, physician and allied health care provider education, community education, and a bone density testing program. All women over the age of 55 years enrolled in the Geisinger Health Plan (GHP) from 1996 to 2000 were included in this analysis. The guidelines led health care providers to increase the evaluation of osteoporosis via bone density measurements and to increase the prescription treatment of osteoporosis. Most importantly, the age-adjusted incidence of hip fractures fell significantly in the entire group as well as in several age strata (65–74, 75–84 and 85+ years). Compared with a predictive model of no intervention, there was an overall reduction in health care costs to GHP estimated to be US$7.8 million over a 5 year period. This report is the first to suggest that an organized Osteoporosis Disease Management Program delivered by a health care system can result in increased evaluation and treatment of osteoporosis with a resultant significant decrease in hip fractures while decreasing the total direct costs of care to a health plan.
Literature
1.
go back to reference Ross PD. Osteoporosis: frequency, consequences, and risk factors. Arch Intern Med 1996;156:1399–411.PubMed Ross PD. Osteoporosis: frequency, consequences, and risk factors. Arch Intern Med 1996;156:1399–411.PubMed
2.
go back to reference Lindsay R, Meunier PJ. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost effectiveness analysis. The basis for a guideline for the medical management of osteoporosis. Osteoporos Int 1998;8(Suppl 4):1–88. Lindsay R, Meunier PJ. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost effectiveness analysis. The basis for a guideline for the medical management of osteoporosis. Osteoporos Int 1998;8(Suppl 4):1–88.
3.
go back to reference Ray NF, Chan JK, Thamer M, Melton LJ. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997;12:24–35.PubMed Ray NF, Chan JK, Thamer M, Melton LJ. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997;12:24–35.PubMed
4.
go back to reference Newman ED, Starkey RH, Ayoub WT, et al. Osteoporosis disease management: best practices from the Penn State Geisinger Health System. J Clin Outcomes Manag 2000;7:23–8. Newman ED, Starkey RH, Ayoub WT, et al. Osteoporosis disease management: best practices from the Penn State Geisinger Health System. J Clin Outcomes Manag 2000;7:23–8.
5.
go back to reference AACE clinical practice guidelines for the prevention and treatment of postmenopausal osteoporosis. Endocr Pract 1996;2:155–71. AACE clinical practice guidelines for the prevention and treatment of postmenopausal osteoporosis. Endocr Pract 1996;2:155–71.
6.
go back to reference Kanis JA, Delmas P, Burckhardt P, et al. Guidelines for the diagnosis and management of osteoporosis. Osteoporos Int 1997;7:390–406.PubMed Kanis JA, Delmas P, Burckhardt P, et al. Guidelines for the diagnosis and management of osteoporosis. Osteoporos Int 1997;7:390–406.PubMed
7.
go back to reference Scheiber LB, Torregrosa L. Evaluation and treatment of postmenopausal osteoporosis. Semin Arthritis Rheum 1998;27:245–61.PubMed Scheiber LB, Torregrosa L. Evaluation and treatment of postmenopausal osteoporosis. Semin Arthritis Rheum 1998;27:245–61.PubMed
8.
go back to reference Meunier PJ, Delmas PD, Eastell R, et al. Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. Clin Ther 1999;21:1025–44.PubMed Meunier PJ, Delmas PD, Eastell R, et al. Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. Clin Ther 1999;21:1025–44.PubMed
9.
go back to reference Compston J. Prevention and treatment of osteoporosis: clinical guidelines and new evidence. J R Coll Physicians Lond 2000;34:518–21.PubMed Compston J. Prevention and treatment of osteoporosis: clinical guidelines and new evidence. J R Coll Physicians Lond 2000;34:518–21.PubMed
10.
go back to reference Sambrook P, O'Neill S, Diamond T, et al. Postmenopausal osteoporosis treatment guidelines. Aust Fam Physician 2000;29:751–8.PubMed Sambrook P, O'Neill S, Diamond T, et al. Postmenopausal osteoporosis treatment guidelines. Aust Fam Physician 2000;29:751–8.PubMed
11.
go back to reference Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract 2001;7:294–312. Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract 2001;7:294–312.
12.
go back to reference Gallagher JC, Ettinger B, Gass ML, et al. Management of postmenopausal osteoporosis: position statement of The North American Menopause Society. Menopause 2002;9:84–101.PubMed Gallagher JC, Ettinger B, Gass ML, et al. Management of postmenopausal osteoporosis: position statement of The North American Menopause Society. Menopause 2002;9:84–101.PubMed
13.
go back to reference Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85:4119–24. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85:4119–24.
14.
go back to reference McClung MR, Geusens P, Miller PD, et al. (Hip Intervention Program Study Group). Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333–40.CrossRefPubMed McClung MR, Geusens P, Miller PD, et al. (Hip Intervention Program Study Group). Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333–40.CrossRefPubMed
15.
go back to reference Ettinger B, Black DM, Mitlak BH, et al. (Multiple Outcomes of Raloxifene Evaluation [MORE] Investigators). Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637–45.PubMed Ettinger B, Black DM, Mitlak BH, et al. (Multiple Outcomes of Raloxifene Evaluation [MORE] Investigators). Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637–45.PubMed
16.
go back to reference Newman ED, Hanus P. Improved bone health behavior using community pharmacists as educators. Dis Manage Health Outcomes 2001;9:329–35. Newman ED, Hanus P. Improved bone health behavior using community pharmacists as educators. Dis Manage Health Outcomes 2001;9:329–35.
Metadata
Title
Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenopausal women after 5 years
Authors
E. D. Newman
W. T. Ayoub
R. H. Starkey
J. M. Diehl
G. C. Wood
Publication date
01-02-2003
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 2/2003
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-002-1336-5

Other articles of this Issue 2/2003

Osteoporosis International 2/2003 Go to the issue